Dupilumab Shown to Reduce COPD Exacerbations Substantially i

This data from the NOTUS trial is set to be submitted to the FDA alongside the phase 3 BOREAS trial data later in the year.

Related Keywords

, Georged Yancopoulos , Naimish Patel , Regeneron Pharmaceuticals Inc , Drug Administration , Regeneron Pharmaceuticals , Breakthrough Therapy , Significantly Reduced , Second Positive Phase , Confirming Potential , Become First Approved Biologic , Copd , Pulmonology , Dupilumab , Phase 3 , Dupixent , Exacerbations ,